Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 1
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P106 - The Efficacy and Safety of Bevacizumab Combined with Chemotherapy in the Treatment of Drug-Resistant SCLC (ID 153)
00:00 - 00:00 | Author(s): S. Wang
To explore the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of drug-resistant small cell lung cancer (SCLC).
Of the 25 patients, 5 patients achieved partial response, 16 patients achieved stable disease, 4 patients achieved progressive disease, and no patients achieved complete response. The short-term effective rate was 20% (5/25) and the clinical benefit rate was 84% (21/25). PFS ranged from 2 months to 6.3 months, and the median PFS was 3.7 months. OS ranged from 5.0 to 12.0 months, with a median OS of 7.6 months. Five patients were still alive as of April 10, 2018. Common toxic and side effects are myelosuppression, alimentary tract reaction and alopecia.
Bevacizumab combined with chemotherapy is effective in the treatment of drug-resistant small cell lung cancer, and its side effects are tolerable. However, due to the small number of cases observed, the results are biased to a certain extent, it is necessary to establish a large-scale, randomized, double-blind, controlled multi-center clinical study to further confirm its efficacy and safety.